# Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

> **NCT01892527** · PHASE2 · COMPLETED · sponsor: **Armando Santoro, MD** · enrollment: 43 (actual)

## Conditions studied

- Colorectal Cancer Metastatic
- C-met Overexpression

## Interventions

- **DRUG:** Tivantinib (ARQ197)

## Key facts

- **NCT ID:** NCT01892527
- **Lead sponsor:** Armando Santoro, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2016-05
- **Final completion:** 2017-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2022-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01892527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01892527, "Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01892527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*